Regression in thin melanoma is associated with nodal recurrence after a negative sentinel node biopsy

Jill C. Rubinstein, Gang Han, Laura Jackson, Kaleigh Bulloch, Stephan Ariyan, Deepak Narayan, Bonnie G. Rothberg, Dale Han

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Prognostic markers for nodal metastasis in thin melanoma patients are debated. We present a single institution study looking at factors predictive of nodal disease in thin melanoma patients. Retrospective review from 1997 to 2012 identified 252 patients with thin melanoma (≤1 mm) who underwent a sentinel lymph node biopsy (SLNB). Node-positive patients included positive SLNB patients and negative SLNB patients who developed a nodal recurrence (false-negative SLNB). Clinicopathologic characteristics were correlated with nodal status and outcome. Median follow-up was 45.5 months. Twelve of 252 patients (4.8%) were node-positive including six positive SLNB (2.4%) and six false-negative SLNB (2.4%) patients. No clinicopathologic factors were significantly correlated with nodal disease. For the six false-negative SLNB patients, median time to nodal recurrence was 37.5 months. Regression was seen in only 16% of cases, but the rate increased to 60% for false-negative SLNB cases. Both age (odds ratio [OR]: 1.09, 95% CI: 1.01–1.17; P = 0.02) and regression (OR: 8.33, 95% CI: 1.34–52.63; P = 0.02) were significantly associated with nodal recurrence after a negative SLNB on univariable analysis. Nodal disease in thin melanoma patients was seen in 4.8% of cases. Although regression was not correlated with nodal metastasis, it was correlated with a false-negative SLNB. Patients with thin melanoma and regression may need more intensive surveillance after a negative SLNB. Further study is needed to determine if the same immune mechanisms that result in regression in primary tumors also lead to regression in lymph nodes, which may decrease detection of melanoma nodal metastases.

Original languageEnglish (US)
Pages (from-to)2832-2840
Number of pages9
JournalCancer medicine
Volume5
Issue number10
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Fingerprint

Sentinel Lymph Node Biopsy
Melanoma
Biopsy
Recurrence
Neoplasm Metastasis
cyhalothrin
Odds Ratio
Lymph Nodes

Keywords

  • Nodal recurrence
  • regression
  • sentinel lymph node biopsy
  • thin melanoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Rubinstein, J. C., Han, G., Jackson, L., Bulloch, K., Ariyan, S., Narayan, D., ... Han, D. (2016). Regression in thin melanoma is associated with nodal recurrence after a negative sentinel node biopsy. Cancer medicine, 5(10), 2832-2840. https://doi.org/10.1002/cam4.922

Regression in thin melanoma is associated with nodal recurrence after a negative sentinel node biopsy. / Rubinstein, Jill C.; Han, Gang; Jackson, Laura; Bulloch, Kaleigh; Ariyan, Stephan; Narayan, Deepak; Rothberg, Bonnie G.; Han, Dale.

In: Cancer medicine, Vol. 5, No. 10, 01.10.2016, p. 2832-2840.

Research output: Contribution to journalArticle

Rubinstein, JC, Han, G, Jackson, L, Bulloch, K, Ariyan, S, Narayan, D, Rothberg, BG & Han, D 2016, 'Regression in thin melanoma is associated with nodal recurrence after a negative sentinel node biopsy', Cancer medicine, vol. 5, no. 10, pp. 2832-2840. https://doi.org/10.1002/cam4.922
Rubinstein JC, Han G, Jackson L, Bulloch K, Ariyan S, Narayan D et al. Regression in thin melanoma is associated with nodal recurrence after a negative sentinel node biopsy. Cancer medicine. 2016 Oct 1;5(10):2832-2840. https://doi.org/10.1002/cam4.922
Rubinstein, Jill C. ; Han, Gang ; Jackson, Laura ; Bulloch, Kaleigh ; Ariyan, Stephan ; Narayan, Deepak ; Rothberg, Bonnie G. ; Han, Dale. / Regression in thin melanoma is associated with nodal recurrence after a negative sentinel node biopsy. In: Cancer medicine. 2016 ; Vol. 5, No. 10. pp. 2832-2840.
@article{8b9ff337a75841e9a0ef2798725b9277,
title = "Regression in thin melanoma is associated with nodal recurrence after a negative sentinel node biopsy",
abstract = "Prognostic markers for nodal metastasis in thin melanoma patients are debated. We present a single institution study looking at factors predictive of nodal disease in thin melanoma patients. Retrospective review from 1997 to 2012 identified 252 patients with thin melanoma (≤1 mm) who underwent a sentinel lymph node biopsy (SLNB). Node-positive patients included positive SLNB patients and negative SLNB patients who developed a nodal recurrence (false-negative SLNB). Clinicopathologic characteristics were correlated with nodal status and outcome. Median follow-up was 45.5 months. Twelve of 252 patients (4.8{\%}) were node-positive including six positive SLNB (2.4{\%}) and six false-negative SLNB (2.4{\%}) patients. No clinicopathologic factors were significantly correlated with nodal disease. For the six false-negative SLNB patients, median time to nodal recurrence was 37.5 months. Regression was seen in only 16{\%} of cases, but the rate increased to 60{\%} for false-negative SLNB cases. Both age (odds ratio [OR]: 1.09, 95{\%} CI: 1.01–1.17; P = 0.02) and regression (OR: 8.33, 95{\%} CI: 1.34–52.63; P = 0.02) were significantly associated with nodal recurrence after a negative SLNB on univariable analysis. Nodal disease in thin melanoma patients was seen in 4.8{\%} of cases. Although regression was not correlated with nodal metastasis, it was correlated with a false-negative SLNB. Patients with thin melanoma and regression may need more intensive surveillance after a negative SLNB. Further study is needed to determine if the same immune mechanisms that result in regression in primary tumors also lead to regression in lymph nodes, which may decrease detection of melanoma nodal metastases.",
keywords = "Nodal recurrence, regression, sentinel lymph node biopsy, thin melanoma",
author = "Rubinstein, {Jill C.} and Gang Han and Laura Jackson and Kaleigh Bulloch and Stephan Ariyan and Deepak Narayan and Rothberg, {Bonnie G.} and Dale Han",
year = "2016",
month = "10",
day = "1",
doi = "10.1002/cam4.922",
language = "English (US)",
volume = "5",
pages = "2832--2840",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - Regression in thin melanoma is associated with nodal recurrence after a negative sentinel node biopsy

AU - Rubinstein, Jill C.

AU - Han, Gang

AU - Jackson, Laura

AU - Bulloch, Kaleigh

AU - Ariyan, Stephan

AU - Narayan, Deepak

AU - Rothberg, Bonnie G.

AU - Han, Dale

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Prognostic markers for nodal metastasis in thin melanoma patients are debated. We present a single institution study looking at factors predictive of nodal disease in thin melanoma patients. Retrospective review from 1997 to 2012 identified 252 patients with thin melanoma (≤1 mm) who underwent a sentinel lymph node biopsy (SLNB). Node-positive patients included positive SLNB patients and negative SLNB patients who developed a nodal recurrence (false-negative SLNB). Clinicopathologic characteristics were correlated with nodal status and outcome. Median follow-up was 45.5 months. Twelve of 252 patients (4.8%) were node-positive including six positive SLNB (2.4%) and six false-negative SLNB (2.4%) patients. No clinicopathologic factors were significantly correlated with nodal disease. For the six false-negative SLNB patients, median time to nodal recurrence was 37.5 months. Regression was seen in only 16% of cases, but the rate increased to 60% for false-negative SLNB cases. Both age (odds ratio [OR]: 1.09, 95% CI: 1.01–1.17; P = 0.02) and regression (OR: 8.33, 95% CI: 1.34–52.63; P = 0.02) were significantly associated with nodal recurrence after a negative SLNB on univariable analysis. Nodal disease in thin melanoma patients was seen in 4.8% of cases. Although regression was not correlated with nodal metastasis, it was correlated with a false-negative SLNB. Patients with thin melanoma and regression may need more intensive surveillance after a negative SLNB. Further study is needed to determine if the same immune mechanisms that result in regression in primary tumors also lead to regression in lymph nodes, which may decrease detection of melanoma nodal metastases.

AB - Prognostic markers for nodal metastasis in thin melanoma patients are debated. We present a single institution study looking at factors predictive of nodal disease in thin melanoma patients. Retrospective review from 1997 to 2012 identified 252 patients with thin melanoma (≤1 mm) who underwent a sentinel lymph node biopsy (SLNB). Node-positive patients included positive SLNB patients and negative SLNB patients who developed a nodal recurrence (false-negative SLNB). Clinicopathologic characteristics were correlated with nodal status and outcome. Median follow-up was 45.5 months. Twelve of 252 patients (4.8%) were node-positive including six positive SLNB (2.4%) and six false-negative SLNB (2.4%) patients. No clinicopathologic factors were significantly correlated with nodal disease. For the six false-negative SLNB patients, median time to nodal recurrence was 37.5 months. Regression was seen in only 16% of cases, but the rate increased to 60% for false-negative SLNB cases. Both age (odds ratio [OR]: 1.09, 95% CI: 1.01–1.17; P = 0.02) and regression (OR: 8.33, 95% CI: 1.34–52.63; P = 0.02) were significantly associated with nodal recurrence after a negative SLNB on univariable analysis. Nodal disease in thin melanoma patients was seen in 4.8% of cases. Although regression was not correlated with nodal metastasis, it was correlated with a false-negative SLNB. Patients with thin melanoma and regression may need more intensive surveillance after a negative SLNB. Further study is needed to determine if the same immune mechanisms that result in regression in primary tumors also lead to regression in lymph nodes, which may decrease detection of melanoma nodal metastases.

KW - Nodal recurrence

KW - regression

KW - sentinel lymph node biopsy

KW - thin melanoma

UR - http://www.scopus.com/inward/record.url?scp=84992472497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992472497&partnerID=8YFLogxK

U2 - 10.1002/cam4.922

DO - 10.1002/cam4.922

M3 - Article

C2 - 27671840

AN - SCOPUS:84992472497

VL - 5

SP - 2832

EP - 2840

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 10

ER -